Wang Jia

Wang Jia

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

27 September 2024 in Cancer Letters
Verified
Journal Article
Closed access
YZYang Zhao
Yang Zhao
DZDainan Zhang
Dainan Zhang
BMBo Meng
Bo Meng
YZYong Zhang
Yong Zhang
SMShunchang Ma
Shunchang Ma
WJWang Jia
Wang Jia

12 March 2021 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
DZDainan Zhang
Dainan Zhang
SMShunchang Ma
Shunchang Ma
CZChuanbao Zhang
Chuanbao Zhang
PLPeiliang Li
Peiliang Li
BMBeibei Mao
Beibei Mao
WJWang Jia
Wang Jia
MicroRNAs (miRNAs) are involved in human glioblastoma (GB). MiR-935 has been reported to have both tumor-inhibiting and tumorigenesis effects, but its role in GB remains unclear. Because of the high mortality and morbidity associated with the malignancy of GB, a deeper understanding of the molecular crosstalk that occurs in GB is needed to identify new potential targets for treatment. At present, the mechanism of GB at the molecular level is not fully understood. With the aid of bioinformatic analysis, miR-935 was significantly downregulated in GB, and it presented a poorer outcome. In the glioma cell line and in the nude mice model, the miR-935 inhibited cell proliferation by modulating cell circles in vitro and in vivo . Then, the target genes of miR-935 were analyzed by using the online database, and the direct binding was tested with a luciferase analysis. FZD6 was found to be the direct target of miR-935. The effect of miR-935 was recovered by the overexpression of FZD6 in vitro . In addition, the negative correlation of miR-935 and the expression of FZD6 were confirmed in our clinical samples, and the expression of FZD6 has a strong correlation with tumor malignancy and prognosis. This study showed that miR-935 directly inhibited the expression of FZD6 and inhibited the cell proliferation, thereby suppressing the development of GB, suggesting that miR-935 is a cancer suppressor miRNA and may become a prognostic biomarker or a promising potential therapeutic target for human GBs.

1 May 2018 in World Neurosurgery
Verified
Journal Article
Closed access
CLCheng-Bei Li
Cheng-Bei Li
MXMing-Guo Xie
Ming-Guo Xie
JMJun-Peng Ma
Jun-Peng Ma
LWLiang Wang
Liang Wang
SHShuyu Hao
Shuyu Hao
Zhen WuZhen Wu
Zhen Wu

10 August 2021 in Journal of Cellular and Molecular Medicine
Verified
Journal Article
Open access
PDF file
MXMeng Xiao
Meng Xiao
CDChaoyang Du
Chaoyang Du
CZChuanbo Zhang
Chuanbo Zhang
XZXinzhong Zhang
Xinzhong Zhang
SLShaomin Li
Shaomin Li
WJWang Jia
Wang Jia
Glioma is the most common malignancy of the nervous system with high rates of recurrence and mortality, even after surgery. The 5‐year survival rate is only about 5%. NEK8 is involved in multiple biological processes in a variety of cancers; however, its role in glioma is still not clear. In the current study, we evaluated the prognostic value of NEK8, as well as its role in the pathogenesis of glioma. Using a bioinformatics approach and RNA‐seq data from public databases, we found that NEK8 expression is elevated in glioma tissues; we further verified this result by RT‐PCR, Western blotting and immunochemistry using clinical samples. Functional enrichment analyses of genes with correlated expression indicated that elevated NEK8 expression is associated with increased immune cell infiltration in glioma and may affect the tumour microenvironment via the regulation of DNA damage/repair. Survival analyses revealed that high levels of NEK8 are associated with a poorer prognosis; higher WHO grade, IDH status, 1p/19q codeletion, age and NEK8 were identified as an independent prognostic factor. These findings support the crucial role of NEK8 in the progression of glioma via effects on immune cell infiltration and suggest that it is a new prognostic biomarker.

26 January 2026 in Nature Communications
Verified
Journal Article
Open access
PDF file
ZYZhenyu Yang
Zhenyu Yang
SWShiyou Wei
Shiyou Wei
HDHao Duan
Hao Duan
XWXiuqi Wang
Xiuqi Wang
DZDainan Zhang
Dainan Zhang
GZGao Zhang
Gao Zhang
The molecular heterogeneity of brain metastases hampers therapeutic development for cures. To address this unmet and urgent need, we construct a comprehensive multi-omic, single cell, and spatially resolved atlas of 1,032 pan-cancer brain metastases, identifying four robust molecular subtypes with distinct biological programs and clinical associations. These brain metastases subtypes (BrMS) are defined by unique biological states: neural-like (BrMS1), metabolic (BrMS3), highly proliferative/immune-excluded (BrMS4), and an immune-infiltrated (BrMS2) state featuring a coordinated epithelial-mesenchymal transition program. Patient-derived organoids coupled with targeted drug screening indicate subtype-specific molecular dependencies and putative targets, notably mTOR signaling activation in BrMS3 and CDK4/6 axis activation in BrMS4, while BrMS1 and BrMS2 display distinct radiobiologic and immunologic signatures. This atlas provides a rigorous classification framework of BrMs and offers insights into subtype-specific molecular vulnerabilities.